OncoMatch/Clinical Trials/NCT06518434
A Pilot Study on the Effect of Cannabis Oil in Untreatable Liver Cancer Patients
Is NCT06518434 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies Medical Cannabis for hepatocellular carcinoma.
Treatment: Medical Cannabis — to study the anti-tumor effect of cannabis oil (THC10% / CBD5%) in untreatable HCC patients based on mRECIST and RECIST criteria
Check if I qualifyExtracted eligibility criteria
Cancer type
Hepatocellular Carcinoma
Prior therapy
Cannot have received: systemic treatment
Previous systemic treatment for HCC
Lab requirements
Liver function
Non-cirrhosis or Child Pugh A cirrhosis; Child Pugh B or C cirrhosis [excluded]
Cardiac function
No myocardial infarction or clinically significant cardiac dysfunction within the last 12 months; no cardiac disorder that would put participant at risk of clinically significant arrhythmia or myocardial infarction
Non-cirrhosis or Child Pugh A cirrhosis; Child Pugh B or C cirrhosis [excluded]; Patients who have experienced a myocardial infarction or clinically significant cardiac dysfunction within the last 12 months or have had a cardiac disorder that, in the opinion of the investigator would have put the participant at risk of a clinically significant arrhythmia or myocardial infarction.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify